N. Leighl

The Cost-Effectiveness of Second-Line Crizotinib in Eml4-Alk Rearranged Advanced Non-Small Cell Lung Cancer.

M. Tsao, J. Hoch, D. Graham, 2014, Value in Health.

ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell Lung Cancer.

P. Jänne, I. Wistuba, L. Sequist, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer.

T. Stockley, E. Chen, D. Graham, 2021, Lung cancer.

The economic impact of the transition from branded to generic oncology drugs.

Bingshu E. Chen, K. Ding, D. Tu, 2016, Current oncology.

P48.05 Is Relapse-Free Survival at 2-Years an Appropriate Surrogate for Overall Survival at 5-Years in EGFR-mutated Resected NSCLC?

A. Sacher, P. Bradbury, G. Liu, 2021, Journal of Thoracic Oncology.

398TiP MARIPOSA-2: Randomized phase III study of amivantamab + lazertinib + chemotherapy vs chemotherapy alone in EGFR-mutant NSCLC after osimertinib failure

S. Li, R. Knoblauch, K. Reckamp, 2022, Annals of Oncology.

LBA61 First analysis of RAIN-701: Study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations & other solid tumours with NRG1/ERBB gene fusions

Erin L. Schenk, T. Burns, D. Camidge, 2020 .

A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours

J. Neal, H. Wakelee, A. Razak, 2012, British Journal of Cancer.

PCN11 PHARMACOECONOMIC ANALYSES OF ERLOTINIB COMPARED WITH BEST SUPPORTIVE CARE (BSC) FOR THE TREATMENT OF RELAPSED NON-SMALL CELL LUNG CANCER (NSCLC) FROM THE CANADIAN PUBLIC HEALTH CARE PERSPECTIVE

I. Côté, I Côté, Nb Leighl, 2006 .